Steve Jobs’ son raises $200M for cancer-focused venture fund

Yosemite is one of a new class of biotech venture funds that also includes the recently launched Dimension and Cure Ventures.

By Gwendolyn Wu • Aug. 2, 2023

A once buzzy gene therapy startup lays off staff and shuts down

Intergalactic, a developer of non-viral gene therapies built by ex-Biogen executive Michael Ehlers, is folding less than two years after its launch. 

By Kristin Jensen • Aug. 2, 2023

Explore the Trendline➔

Cell therapy

The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.

By BioPharma Dive staff

TG shares tumble following licensing deal for MS drug

Some on Wall Street believe the New York-based biotechnology company is now less likely to get acquired after agreeing to sell partial rights to its only marketed product.

By Jacob Bell • Aug. 1, 2023

BridgeBio explores path forward for muscular disease drug

According to the company, FDA officials have signaled openness to using a surrogate endpoint for assessing accelerated approval of a treatment for limb-girdle muscular dystrophy.

By Ned Pagliarulo • July 31, 2023

Apellis faces safety doubts for fast-selling eye drug

At a medical meeting, the company confirmed seven cases of a rare, but severe, side effect have been reported following treatment with its geographic atrophy drug Syfovre.

By Ben Fidler • Updated July 31, 2023

Early-stage biotech funding on pace to drop 40% in 2023, HSBC report shows

Investment in drugmaking “platforms” is declining as venture firms turn to safer bets, according to a study from the new startup-focused division of HSBC.

By Gwendolyn Wu • July 28, 2023

Biogen to acquire rare disease drugmaker Reata for $7.3B

The deal is a major bet by Biogen and its new CEO Chris Viehbacher, who’s reorganized R&D, cut costs and laid off staff since becoming company head last year.

By Ned Pagliarulo • Updated July 28, 2023

Gene editing biotech Homology hits reset and seeks a sale

The company will lay off 87% of its workforce and halt further research, including for a gene editing therapy to treat the rare disease PKU.

By Ned Pagliarulo • July 28, 2023

European VC Medicxi raises $400M for ‘asset-centric’ biotech investing

Several biotech investors have announced new investment funds in 2023 despite a turbulent market that's challenged startups.

By Gwendolyn Wu • July 27, 2023

FDA declines to review Biohaven’s latest drug in setback to pipeline

While the FDA doesn’t think the brain disease treatment merits an evaluation, Biohaven is still pushing for one and has requested a further meeting.

By Delilah Alvarado • July 27, 2023

Kincell spins out of cell therapy biotech, joining wave of manufacturing startups

The company is the latest to emerge with plans to make production of cell-based medicines easier for researchers and biotechs.

By Ben Fidler • July 26, 2023

Infinity to lay off staff, offload cancer drug after merger falls apart

The cost cuts at the nearly 30-year-old biotech are part of plans to seek a “strategic transaction” for the company’s only remaining drug prospect.

By Ben Fidler • July 26, 2023

Nexo allies with MD Anderson in pursuit of covalent cancer drugs

The startup raised $60 million, joining other covalent drug developers like Matchpoint, Terremoto and Enlaza in drawing investor interest.

By Gwendolyn Wu • July 26, 2023

Biogen to eliminate 1,000 jobs in further cost cuts

CEO Chris Viehbacher described the restructuring, which will trim $1 billion in operating expenses, as a “complete redesign of Biogen.”

By Ned Pagliarulo • Updated July 25, 2023

FibroGen CEO resigns amid latest round of layoffs

The biotech’s leader Enrique Conterno is stepping down for personal reasons after a string of clinical setbacks that led to a restructuring. Eli Lilly veteran Thane Wettig will replace him in the interim.

By Delilah Alvarado • July 25, 2023

Editas names Biogen veteran as top scientist in latest executive change

Linda Burkly’s appointment follows the exit of CSO Mark Shearman, whose departure Editas announced alongside layoffs earlier this year.

By Gwendolyn Wu • July 24, 2023

Roche buys into Alnylam heart drug in cardiovascular research bet

The Swiss pharma company is the latest large drugmaker to invest big in an experimental heart treatment, after years of prioritizing medicines for cancer and immune diseases.

By Ned Pagliarulo • July 24, 2023

Hunting Host Cell Proteins (HCPs) with mass spectrometry

Regulators are recognizing mass spectrometry as a powerful tool in Host Cell Protein analysis. Are you ready to implement HCP-MS?

July 24, 2023

Mirati’s KRAS-blocking cancer drug hits setback in Europe

A key committee for the European Medicines Agency recommended against approval of the targeted therapy. Mirati said it intends to appeal the decision.

By Ned Pagliarulo • July 21, 2023

Idorsia warns of up to 500 layoffs as part of cost-cutting initiative

The Swiss drugmaker now joins a lengthy list of biotechs that, amid a drawn-out market downturn, have turned to job cuts and research reevaluations to save money.

By Jacob Bell • July 21, 2023

Cell therapy startup Turnstone adds to biotech IPO flurry with $80M raise

The offering is a financial lifeline for Turnstone and the fourth for the sector this month, the first time that’s happened in nearly a year and a half, according to BioPharma Dive data.

By Ben Fidler • July 21, 2023

Swiss startup LimmaTech licenses GSK vaccine, hires ex-CureVac chief as CEO

The startup will take on development of a shigellosis vaccine GSK inherited when it acquired LimmaTech’s predecessor, GlycoVaxyn, in 2015. 

By Kristin Jensen • July 20, 2023

Amarin, Fibrogen lay off staff as biotech cost cutting continues

The two drugmakers moved to trim costs following clinical and commercial setbacks, joining a lengthening list of biotechs forced into similar restructurings.

By Delilah Alvarado • July 19, 2023

Argenx raises $1.1B on heels of rare disease drug data

The follow-on stock offering is particularly large for a biotechnology company and will bolster the financial position of Argenx, now worth nearly $30 billion.

By Ned Pagliarulo • July 19, 2023

A cancer biotech’s collapse gives Neurogene a path to Wall Street

The startup, a developer of gene therapies for brain diseases like Rett syndrome, will bypass an IPO by merging with struggling drugmaker Neoleukin.

By Delilah Alvarado • July 18, 2023